AstraZeneca Pharma India Limited Overview
Get informed when a big investor buys or sells
+ Follow19.43%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
AstraZeneca Pharma India Limited (ASTRAZEN.BO) currently reports a ROE of 19.43%. That is above the sector sector average of 11.85%. Use the charts on this page to explore AstraZeneca Pharma India Limited's ROE history and peer comparisons.
AstraZeneca Pharma India Limited's ROE of 19.43% is higher than the its sector sector average of 11.85%. That is roughly 64.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but AstraZeneca Pharma India Limited's current 19.43% should be judged against industry norms (sector average: 11.85%) and against ASTRAZEN.BO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 19.43%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.85%. From there, open related valuation or income-statement pages for AstraZeneca Pharma India Limited, and consider following ASTRAZEN.BO for alerts when major investors trade the stock.
